Teva Acquires Emalex Biosciences for $700M to Advance Ecopipam NDA in Pediatric Tourette Syndrome

Teva Pharmaceutical Industries has closed its acquisition of Emalex Biosciences, bringing a late-stage neuroscience asset within reach of a U.S. NDA submission anticipated in H2 2026, a timeline that puts regulatory affairs and CMC teams on notice now. The deal adds ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome, to Teva's innovative pipeline at a point where Phase 3 data are already in the public domain.

At closing, Teva paid $700 million in upfront consideration. Up to an additional $200 million in commercial milestone payments, plus net sales-based royalties, is contingent on commercialization and regulatory approval. Emalex was created by Paragon Biosciences specifically to advance CNS assets; Paragon supported the program through clinical development and NDA compilation.

Ecopipam carries FDA Orphan Drug and Fast Track designations for pediatric Tourette syndrome, a patient population capped at 200,000 under Orphan Drug criteria. Phase 3 results, published in JAMA Neurology, met the primary efficacy endpoint: time to relapse in pediatric patients stable on ecopipam then randomized to drug or placebo reached statistical significance (p = 0.0084). The most common treatment-related adverse events were somnolence (10.2%), insomnia (7.4%), anxiety (6.0%), fatigue (5.6%), and headache (5.1%).

For QA and regulatory leads inheriting this program, the Fast Track designation carries defined FDA interaction obligations that will shape submission planning and review timelines. The Orphan Drug designation introduces post-approval exclusivity considerations relevant to lifecycle management and labeling strategy under 21 CFR Part 316.

Teva has framed the acquisition as consistent with its Pivot to Growth strategy, emphasizing capital-efficient business development in focused therapeutic areas. Neuroscience is an established Teva franchise, the company markets AJOVY (fremanezumab) in migraine, which provides an existing commercial and medical affairs infrastructure that ecopipam can be built against, assuming NDA approval.

Current pharmacological options for Tourette syndrome offer incomplete tic control for a meaningful share of the pediatric population, and tolerability constraints limit uptake of existing agents. Ecopipam's D1 receptor mechanism is pharmacologically distinct from approved therapies, a differentiation point that will feature prominently in the NDA's clinical section and any subsequent label negotiations.

The NDA submission window in the second half of 2026 sets a near-term milestone against which Teva's regulatory and manufacturing readiness will be measured.

Source: Teva Pharmaceutical Industries via GlobeNewswire, June 10, 2026.